Mr. William F. McKeon

Mr. William F. McKeon

President and CEO, Texas Medical Center

William “Bill” McKeon is the President and Chief Executive Officer of the Texas Medical Center. He is responsible for driving strategic, operational and programmatic initiatives across the Texas Medical Center’s member institutions to enhance its leadership position in the life sciences. McKeon joined the Texas Medical Center in 2013 as executive vice president, chief operating officer and chief strategy officer.

McKeon attended Roger Williams University on the Harold G. Way Scholarship for Leadership and Academic Excellence. He worked throughout his college years as a legal intern at Asquith, Merolla, Anderson, Ryan & Wiley – a prestigious law firm in Providence, Rhode Island. He graduated with top honors with a Bachelor of Science in Legal Studies. He earned his master’s degree from University of San Francisco School of Management.

McKeon began his professional career at Du Pont de Nemours. He initially led the implementation of large news publishing systems around the world and was later promoted to run marketing and business development. During his time at Du Pont, McKeon lived throughout the United States, United Kingdom and Sweden. His career shifted to health care when he was recruited to Stanford University Medical Center, where he initially led the Cardiovascular Medicine and Cardiothoracic Surgery business. He was then promoted to Director of Market Development for all 17 business lines at Stanford.

He then went to Raytel Medical Systems - the largest cardiac monitoring business in the United States. He served as Executive Director and digitized all businesses so that physicians could see patients’ EKGs online from anywhere in the world. At Raytel, he won the Computer World Smithsonian Award in Medicine.
McKeon came to Houston to join U.S. Oncology, which provides cancer care for over 25 percent of the U.S. population. There, he served as Senior Vice President of Marketing and Pharmaceutical Business Relations. During McKeon’s tenure, U.S. Oncology grew from $250 million to $1.4 billion, filed for IPO and was later acquired by the McKesson Corporation.

McKeon then moved to Medtronic Inc., the largest medical device company in the world. He led Strategy and Emerging Technologies across all of the Medtronic businesses. His main focus was to define the digital strategy for all Medtronic medical devices so that they could connect to cellular devices.

McKeon was then recruited to serve as President and CEO of Microport Inc. in Shanghai. He grew the business from $17 million to $157 million in two years. Additionally, he diversified the business from one line to four lines and prepared the company for IPO. Today, Microport is listed on the Hong Kong stock exchange.
McKeon then moved to London to serve as President and CEO of Cellnovo, the first mobile diabetes management system in the world. He raised $10 million for its Series A round and $57 million for the Series B. Cellnovo is public on the European Exchange.